NASDAQ:PRAH

PRA Health Sciences Stock Forecast, Price & News

$132.26

-2.40 (-1.78 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$130.66

Now: $132.26▼

$134.56

50-Day Range

$112.48

MA: $123.38▼

$136.53

52-Week Range

$58.67

Now: $132.26▼

$137.88

Volume342,200 shs

Average Volume282,736 shs

Market Capitalization$8.48 billion

P/E Ratio38.67

Dividend YieldN/A

Beta1.24

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

MarketRank^™

Overall MarketRank^™

1.46 out of 5 stars

Medical Sector

468th out of 1,923 stocks

Commercial Physical Research Industry

10th out of 42 stocks

1.2 Analyst's Opinion

Consensus Rating
PRA Health Sciences has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $110.20, PRA Health Sciences has a forecasted downside of 16.7% from its current price of $132.26.
Amount of Analyst Coverage
PRA Health Sciences has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
PRA Health Sciences has received 365 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PRA Health Sciences has received 341 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
PRA Health Sciences has received 51.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote “Outperform” if you believe PRAH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PRA Health Sciences does not currently pay a dividend.
Dividend Growth
PRA Health Sciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PRA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,416,450.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of PRA Health Sciences is held by insiders.
Percentage Held by Institutions
96.14% of the stock of PRA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for PRA Health Sciences are expected to grow by 32.47% in the coming year, from $3.85 to $5.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PRA Health Sciences is 38.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.03.
Price to Earnings Ratio vs. Sector
The P/E ratio of PRA Health Sciences is 38.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 35.64.
Price to Earnings Growth Ratio
PRA Health Sciences has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
PRA Health Sciences has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PRAH

Previous Symbol

CUSIPN/A

CIK1613859

Webwww.prahs.com

Phone919-786-8200

Employees17,500

Debt

Debt-to-Equity Ratio0.95

Current Ratio1.13

Quick Ratio1.13

Price-To-Earnings

Trailing P/E Ratio38.67

Forward P/E Ratio34.35

P/E Growth2.26

Sales & Book Value

Annual Sales$3.07 billion

Price / Sales2.77

Cash Flow$7.08 per share

Price / Cash Flow18.67

Book Value$17.23 per share

Price / Book7.68

Profitability

EPS (Most Recent Fiscal Year)$4.80

Net Income$243.02 million

Net Margins7.09%

Return on Equity22.21%

Return on Assets7.04%

Miscellaneous

Outstanding Shares64,150,000

Market Cap$8.48 billion

Next Earnings Date2/18/2021 (Estimated)

OptionableOptionable

$132.26

-2.40 (-1.78 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock price been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRAH shares have increased by 49.1% and is now trading at $132.26.
View which stocks have been most impacted by COVID-19.

Is PRA Health Sciences a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRA Health Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAH, but not buy additional shares or sell existing shares.
View analyst ratings for PRA Health Sciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PRA Health Sciences?

Wall Street analysts have given PRA Health Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PRA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Colin Shannon's approval rating as PRA Health Sciences' CEO?

500 employees have rated PRA Health Sciences CEO Colin Shannon on Glassdoor.com. Colin Shannon has an approval rating of 87% among PRA Health Sciences' employees.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for PRA Health Sciences.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) announced its quarterly earnings results on Wednesday, November, 4th. The medical research company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.14 by $0.16. The medical research company earned $796.31 million during the quarter, compared to the consensus estimate of $769.14 million. PRA Health Sciences had a net margin of 7.09% and a trailing twelve-month return on equity of 22.21%. The business's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 EPS.
View PRA Health Sciences' earnings history.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its fourth quarter earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of $1.41-1.51 for the period, compared to the Thomson Reuters consensus estimate of $1.42. The company issued revenue guidance of $810-840 million, compared to the consensus revenue estimate of $818.00 million.

What price target have analysts set for PRAH?

11 Wall Street analysts have issued 12 month price objectives for PRA Health Sciences' shares. Their forecasts range from $89.00 to $145.00. On average, they anticipate PRA Health Sciences' share price to reach $110.20 in the next year. This suggests that the stock has a possible downside of 16.7%.
View analysts' price targets for PRA Health Sciences or view Wall Street analyst' top-rated stocks.

Who are some of PRA Health Sciences' key competitors?

Some companies that are related to PRA Health Sciences include Exact Sciences (EXAS), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), ICON Public (ICLR), Syneos Health (SYNH), Exelixis (EXEL), Medpace (MEDP), BTG (BTGGF), Precigen (PGEN), National Research (NRC), Starpharma (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Auxly Cannabis Group (CBWTF).
View all of PRAH's competitors.

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), The Walt Disney (DIS), PayPal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:

Mr. Colin Shannon, Chairman, CEO & Pres (Age 61, Pay $1.04M)
Mr. Michael J. Bonello, Exec. VP & CFO (Age 50, Pay $480.54k)
Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
Mr. Christopher L. Gaenzle, Exec. VP, Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 53)
Mr. Thomas Byrne, VP of Legal Affairs
Laurie Hurst, Sr. Director of Communications & PR
Ms. Tami Klerr-Naivar, Exec. VP and Chief Sales & Marketing Officer
Mr. Patrick R. Spine, VP of HR (Age 49)
Dr. Michael Kirchengast, Sr. VP of Scientific Affairs
Mr. David G. Passov, Sr. VP & Head of Project Management - EAPA

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pendal Group Limited (1.61%), Peregrine Capital Management LLC (0.22%), Scout Investments Inc. (0.14%), Bellecapital International Ltd. (0.08%), State of Alaska Department of Revenue (0.02%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Limited, Pacer Advisors Inc., and Bowling Portfolio Management LLC. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences or view top insider-selling stocks.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bellecapital International Ltd., Scout Investments Inc., State of Alaska Department of Revenue, International Assets Investment Management LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for PRA Health Sciences or or view top insider-buying stocks.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $132.26.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $8.48 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here